| Namita Jain Gupta, MD | |
|
1 Riverview Plz, Red Bank, NJ 07701-1864 | |
| (732) 528-1142 | |
| Not Available |
| Full Name | Namita Jain Gupta |
|---|---|
| Gender | Female |
| Speciality | Pathology |
| Experience | 25 Years |
| Location | 1 Riverview Plz, Red Bank, New Jersey |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1255591905 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207ZP0102X | Pathology - Anatomic Pathology & Clinical Pathology | 234950 (Massachusetts) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Riverview Medical Center | Red bank, NJ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Optum Medical Care Of New Jersey Pc | 3072650290 | 231 |
| Sarwan S Kahlam, Md, Llc | 4082756093 | 2 |
| Meridian Laboratory Physicians, Pa | 5193707032 | 16 |
News Archive
StemCells, Inc., a leading stem cell company developing and commercializing novel stem cell therapeutics and tools for use in stem cell-based research and drug discovery, today reported financial results and business highlights for the second quarter ended June 30, 2010.
A new population-based study has found that patients with glioblastoma who died in 2010, after the Food and Drug Administration (FDA) approval of bevacizumab, had lived significantly longer than patients who died of the disease in 2008, prior to the conditional approval of the drug for the treatment of the deadly brain cancer. Bevacizumab is used to treat patients with certain cancers whose cancer has spread. The study appears in the journal Cancer.
In a recent clinical trial, non-HIV-infected individuals who used the antiretroviral drug Truvada on a daily basis cut their risk of becoming infected with HIV by 44 percent.
A team of researchers at the IRCM, led by Andr- Veillette, MD, explains how our immune system kills abnormal blood cells. Their discovery, recently published in the Journal of Experimental Medicine, could eventually lead to new treatment avenues for leukemia, lymphoma and certain types of infectious viral diseases.
› Verified 3 days ago
| Entity Name | Meridian Laboratory Physicians, Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1104903723 PECOS PAC ID: 5193707032 Enrollment ID: O20040603001035 |
News Archive
StemCells, Inc., a leading stem cell company developing and commercializing novel stem cell therapeutics and tools for use in stem cell-based research and drug discovery, today reported financial results and business highlights for the second quarter ended June 30, 2010.
A new population-based study has found that patients with glioblastoma who died in 2010, after the Food and Drug Administration (FDA) approval of bevacizumab, had lived significantly longer than patients who died of the disease in 2008, prior to the conditional approval of the drug for the treatment of the deadly brain cancer. Bevacizumab is used to treat patients with certain cancers whose cancer has spread. The study appears in the journal Cancer.
In a recent clinical trial, non-HIV-infected individuals who used the antiretroviral drug Truvada on a daily basis cut their risk of becoming infected with HIV by 44 percent.
A team of researchers at the IRCM, led by Andr- Veillette, MD, explains how our immune system kills abnormal blood cells. Their discovery, recently published in the Journal of Experimental Medicine, could eventually lead to new treatment avenues for leukemia, lymphoma and certain types of infectious viral diseases.
› Verified 3 days ago
| Entity Name | Atlantic Coast Urology,pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1265635627 PECOS PAC ID: 1254425226 Enrollment ID: O20070921000007 |
News Archive
StemCells, Inc., a leading stem cell company developing and commercializing novel stem cell therapeutics and tools for use in stem cell-based research and drug discovery, today reported financial results and business highlights for the second quarter ended June 30, 2010.
A new population-based study has found that patients with glioblastoma who died in 2010, after the Food and Drug Administration (FDA) approval of bevacizumab, had lived significantly longer than patients who died of the disease in 2008, prior to the conditional approval of the drug for the treatment of the deadly brain cancer. Bevacizumab is used to treat patients with certain cancers whose cancer has spread. The study appears in the journal Cancer.
In a recent clinical trial, non-HIV-infected individuals who used the antiretroviral drug Truvada on a daily basis cut their risk of becoming infected with HIV by 44 percent.
A team of researchers at the IRCM, led by Andr- Veillette, MD, explains how our immune system kills abnormal blood cells. Their discovery, recently published in the Journal of Experimental Medicine, could eventually lead to new treatment avenues for leukemia, lymphoma and certain types of infectious viral diseases.
› Verified 3 days ago
| Entity Name | Optum Medical Care Of New Jersey Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1578665048 PECOS PAC ID: 3072650290 Enrollment ID: O20091021000129 |
News Archive
StemCells, Inc., a leading stem cell company developing and commercializing novel stem cell therapeutics and tools for use in stem cell-based research and drug discovery, today reported financial results and business highlights for the second quarter ended June 30, 2010.
A new population-based study has found that patients with glioblastoma who died in 2010, after the Food and Drug Administration (FDA) approval of bevacizumab, had lived significantly longer than patients who died of the disease in 2008, prior to the conditional approval of the drug for the treatment of the deadly brain cancer. Bevacizumab is used to treat patients with certain cancers whose cancer has spread. The study appears in the journal Cancer.
In a recent clinical trial, non-HIV-infected individuals who used the antiretroviral drug Truvada on a daily basis cut their risk of becoming infected with HIV by 44 percent.
A team of researchers at the IRCM, led by Andr- Veillette, MD, explains how our immune system kills abnormal blood cells. Their discovery, recently published in the Journal of Experimental Medicine, could eventually lead to new treatment avenues for leukemia, lymphoma and certain types of infectious viral diseases.
› Verified 3 days ago
| Entity Name | Sarwan S Kahlam, Md, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1699976142 PECOS PAC ID: 4082756093 Enrollment ID: O20100128000355 |
News Archive
StemCells, Inc., a leading stem cell company developing and commercializing novel stem cell therapeutics and tools for use in stem cell-based research and drug discovery, today reported financial results and business highlights for the second quarter ended June 30, 2010.
A new population-based study has found that patients with glioblastoma who died in 2010, after the Food and Drug Administration (FDA) approval of bevacizumab, had lived significantly longer than patients who died of the disease in 2008, prior to the conditional approval of the drug for the treatment of the deadly brain cancer. Bevacizumab is used to treat patients with certain cancers whose cancer has spread. The study appears in the journal Cancer.
In a recent clinical trial, non-HIV-infected individuals who used the antiretroviral drug Truvada on a daily basis cut their risk of becoming infected with HIV by 44 percent.
A team of researchers at the IRCM, led by Andr- Veillette, MD, explains how our immune system kills abnormal blood cells. Their discovery, recently published in the Journal of Experimental Medicine, could eventually lead to new treatment avenues for leukemia, lymphoma and certain types of infectious viral diseases.
› Verified 3 days ago
| Entity Name | Digestive Disease Consultants Of North Jersey Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1073804456 PECOS PAC ID: 3375729742 Enrollment ID: O20110519000291 |
News Archive
StemCells, Inc., a leading stem cell company developing and commercializing novel stem cell therapeutics and tools for use in stem cell-based research and drug discovery, today reported financial results and business highlights for the second quarter ended June 30, 2010.
A new population-based study has found that patients with glioblastoma who died in 2010, after the Food and Drug Administration (FDA) approval of bevacizumab, had lived significantly longer than patients who died of the disease in 2008, prior to the conditional approval of the drug for the treatment of the deadly brain cancer. Bevacizumab is used to treat patients with certain cancers whose cancer has spread. The study appears in the journal Cancer.
In a recent clinical trial, non-HIV-infected individuals who used the antiretroviral drug Truvada on a daily basis cut their risk of becoming infected with HIV by 44 percent.
A team of researchers at the IRCM, led by Andr- Veillette, MD, explains how our immune system kills abnormal blood cells. Their discovery, recently published in the Journal of Experimental Medicine, could eventually lead to new treatment avenues for leukemia, lymphoma and certain types of infectious viral diseases.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Namita Jain Gupta, MD 1 Riverview Plz, Red Bank, NJ 07701-1864 Ph: (732) 530-2347 | Namita Jain Gupta, MD 1 Riverview Plz, Red Bank, NJ 07701-1864 Ph: (732) 528-1142 |
News Archive
StemCells, Inc., a leading stem cell company developing and commercializing novel stem cell therapeutics and tools for use in stem cell-based research and drug discovery, today reported financial results and business highlights for the second quarter ended June 30, 2010.
A new population-based study has found that patients with glioblastoma who died in 2010, after the Food and Drug Administration (FDA) approval of bevacizumab, had lived significantly longer than patients who died of the disease in 2008, prior to the conditional approval of the drug for the treatment of the deadly brain cancer. Bevacizumab is used to treat patients with certain cancers whose cancer has spread. The study appears in the journal Cancer.
In a recent clinical trial, non-HIV-infected individuals who used the antiretroviral drug Truvada on a daily basis cut their risk of becoming infected with HIV by 44 percent.
A team of researchers at the IRCM, led by Andr- Veillette, MD, explains how our immune system kills abnormal blood cells. Their discovery, recently published in the Journal of Experimental Medicine, could eventually lead to new treatment avenues for leukemia, lymphoma and certain types of infectious viral diseases.
› Verified 3 days ago
Min Zheng, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 1 Riverview Plz, Red Bank, NJ 07701 Phone: 732-741-2700 Fax: 732-776-4146 | |
Haig Minassian, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 1 Riverview Plz, Dept Of Pathology, Red Bank, NJ 07701 Phone: 732-530-2347 Fax: 732-345-2045 | |
Dr. Kathy Rumi Kawaguchi, M.D. Pathology Medicare: Not Enrolled in Medicare Practice Location: 365 Broad St, Red Bank, NJ 07701 Phone: 732-842-4294 | |
Edwin Leschhorn, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 1 Riverview Plz, Riverview Medical Center Dept Of Pathology, Red Bank, NJ 07701 Phone: 732-530-2347 Fax: 732-345-2045 | |
Zwannah Dukuly, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 1 Riverview Plz, Riverview Medical Center Dept Of Pathology, Red Bank, NJ 07701 Phone: 732-530-2347 Fax: 732-345-2045 |